MedPage Today2h
Studies Point to Several Options for Ulcerative Colitis After Anti-TNF Failure
SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...
Eli Lilly reports sustained Crohn's disease treatment success
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...
Nasdaq2d
Palisade Bio Presents Positive Preclinical Data for PALI-2108 in Ulcerative Colitis at 2025 Crohn’s and Colitis Congress
Palisade Bio, Inc. announced positive preclinical results for its drug candidate PALI-2108 at the 2025 Crohn’s and Colitis Congress ... could be a novel treatment for UC. It effectively converts ...
The American Journal of Managed Care6d
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
EurekAlert!6d
Crohn's & Colitis Congress® spotlights key IBD research findings
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...
Pharmabiz2d
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...
Medindia5d
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...